# EZlifeBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ezlifebio

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Total disclosed funding: $9.9M
- Latest round: Series A (Apr 12, 2017)
- Investors on record: 2

## About

Established in 2015 and based in Guangzhou, China, EZlifeBio is a developer of tumor liquid biopsy technology, providing testing services such as early diagnosis of clinical tumors, efficacy monitoring. In April 2017, new investor Sangel Capital led a CNY 68 million in series A funding for EZlifeBio.

The company provides services such as early diagnosis of clinical tumors, efficacy monitoring, and targeted drug resistance detection.

The company generates revenue by providing testing services for clinical tumor diagnosis, efficacy monitoring and targeted drug resistance detection.

## Funding rounds

- Series A, Apr 12, 2017, $9.9M — Sangel Capital, Alwin Capital

## Investors

- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series A
- Alwin Capital — Series A